Trial of ARV-110 and Abiraterone in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
Phase 1
Active, not recruiting
- Conditions
- Prostate Cancer Metastatic
- Interventions
- Drug: ARV-110 in Combination with Abiraterone
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2025-03-17
- Lead Sponsor
- Arvinas Androgen Receptor, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT05177042
- Locations
- 🇬🇧
Clinical Trial Site, Preston, United Kingdom
Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer
- First Posted Date
- 2019-03-25
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Arvinas Androgen Receptor, Inc.
- Target Recruit Count
- 248
- Registration Number
- NCT03888612
- Locations
- 🇺🇸
Clinical Trial Site, Charlottesville, Virginia, United States
© Copyright 2025. All Rights Reserved by MedPath